Pharma major Lupin announced that it has received final approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1%.

Lupin's Hydrocortisone Butyrate Lotion, 0.1% is the generic version of PreCision's Locoid Lotion, 0.1%. It is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximately USD 13.8 million in the US (IQVIA MAT April 2018).

Shares of the company gained Rs 2.8, or 0.32%, to trade at Rs 872.60. The total volume of shares traded was 78,823 at the BSE (10.28 a.m., Tuesday).